Literature DB >> 2176720

Evidence for presynaptic 5-hydroxytryptamine3 recognition sites on vagal afferent terminals in the brainstem of the ferret.

R A Leslie1, D J Reynolds, P L Andrews, D G Grahame-Smith, C J Davis, J M Harvey.   

Abstract

Antagonists acting at the 5-hydroxytryptamine3 receptor are potent anti-emetic agents in cases of cytotoxic- and radiation-induced vomiting, and binding sites for these compounds have been described in brainstem areas known to be involved in mediation of nausea and vomiting. We have used autoradiography to examine the distribution of one of these antagonists, [3H]granisetron in the caudal brainstem of the ferret, a commonly used animal model for physiological investigations of emesis. The highest density of binding sites was found to be in the dorsomedial region of the nucleus of the solitary tract, the principal terminus for gastric vagal afferent fibres. Lower levels of binding were observed in the area postrema and the dorsal motor nucleus of the vagus. Following unilateral nodose ganglion excision, displaceable binding of [3H]granisetron in the nucleus of the solitary tract was attenuated on the ipsilateral side by 65%. Bilateral subdiaphragmatic vagotomy abolished binding of [3H]granisetron in the entire dorsal vagal complex. These results provide strong circumstantial evidence that 5-hydroxytryptamine3 receptors are located on vagal afferent terminals in the ferret brainstem.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2176720     DOI: 10.1016/0306-4522(90)90060-h

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  21 in total

Review 1.  Neuropharmacology of emesis in relation to clinical response.

Authors:  B Costall; R J Naylor
Journal:  Br J Cancer Suppl       Date:  1992-12

2.  Glucose increases synaptic transmission from vagal afferent central nerve terminals via modulation of 5-HT3 receptors.

Authors:  Shuxia Wan; Kirsteen N Browning
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-09-18       Impact factor: 4.052

Review 3.  Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 4.  Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.

Authors:  G L Plosker; R J Milne
Journal:  Pharmacoeconomics       Date:  1992-10       Impact factor: 4.981

5.  Involvement of the dorsomedial hypothalamus and the nucleus tractus solitarii in chronic cardiovascular changes associated with anxiety in rats.

Authors:  Caroline Sévoz-Couche; Charly Brouillard; Françoise Camus; Dominique Laude; Sietse F De Boer; Chrystel Becker; Jean-Jacques Benoliel
Journal:  J Physiol       Date:  2013-01-07       Impact factor: 5.182

Review 6.  Ondansetron. Therapeutic use as an antiemetic.

Authors:  R J Milne; R C Heel
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

7.  Colocalization of ATP and nicotinic ACh receptors in the identified vagal preganglionic neurone of rat.

Authors:  J Nabekura; S Ueno; T Ogawa; N Akaike
Journal:  J Physiol       Date:  1995-12-01       Impact factor: 5.182

8.  Serotonin activates catecholamine neurons in the solitary tract nucleus by increasing spontaneous glutamate inputs.

Authors:  Ran Ji Cui; Brandon L Roberts; Huan Zhao; Mingyan Zhu; Suzanne M Appleyard
Journal:  J Neurosci       Date:  2012-11-14       Impact factor: 6.167

9.  Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis.

Authors:  T C Chang; F Hsieh; C H Lai; C J Tseng; H H Cheng; C L Li; B J Michael; Y K Soong
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

10.  Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus).

Authors:  Bart C De Jonghe; Charles C Horn
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-02-18       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.